Do Increased Doses to Stem-Cell Niches during Radiation Therapy Improve Glioblastoma Survival?

Table 2

Progression-free and overall survival in regard of dosimetry in glioblastoma patients with conventional fractionated radiotherapy

Cofactors	Number of patients, ≥40 Gy/<40 Gy	Median PFS,; ≥40 Gy	Median PFS,; <40 Gy	value	Median OS,; ≥40 Gy	Median OS,; <40 Gy	value
Mean IL ventricle dose	30/24	9.0 (6.3–11.7)	5.1 (3.5–6.8)	0.11	21.6 (18.5–24.7)	18. (11.2–24.8)	0.15
Mean CL ventricle dose	7/47	10.1 (4.1–16.1)	7.2 (5.0–9.4)	0.26	21.6 (12.6–30.6)	21.2 (16.0–26.5)	0.65
Mean IL SVZ dose	31/23	8.5 (6.3–10.2)	5.2 (3.1–7.3)	0.01	21.3 (17.5–25.2)	18.0 (11.4–24.6)	0.19
Mean CL SVZ dose; (≥30 Gy versus <30 Gy)	12/42	10.1 (8.9–11.3)	6.8 (4.8–9.0)	0.03	21.6 (12.2–31.0)	21.2 (16.4–26.1)	0.29
Mean IL DG dose	22/32	7.3 (5.4–9.2)	7.8 (5.0–10.5)	0.22	20.8 (12.5–29.1)	21.3 (15.6–27.1)	0.49
Mean CL DG dose; (≥30 Gy versus <30 Gy)	4/50	9.4 (0.28–18.6)	7.3 (6.3–8.3)	0.84	15.4 (−5.96–36.8)	21.3 (16.7–25.8)	0.85

CI: confidence interval; HR: hazard ratio; PFS: progression-free survival; OS: overall survival; IL: ipsilateral; CL: contralateral; SVZ: subventricular zone; Gy: gray.